Codexis

machine-learning plus bioinformatics plus automated lab compress design-build-test to about one week, trained on 20+ years of experimental data.

Country
United States
Ticker
CDXS
ISO 9001
Coverage
CNEUINUS
crop-biotech
enzymes-biocatalysis
specialty-fine-chem
therapeutics-platforms
Regulatorsepafdaemanmpareachmoa-chinaefsa

Verifiable facts

FactValueSource
FundingIn July 2026, Codexis raised approximately $25 million in net proceeds through equity financing. (2026-06-30)ir.codexis.com · fool.com
CapacityTargeting 0.5 kilogram scale for siRNA production in the ECO Innovation Lab by the end of 2026; future GMP facility aims for larger scale. (2026-08-18)fool.com
CertificationISO 9001 certified for its in-house manufacturing suite. (2026-03-11)ir.codexis.com
Regulatory approvalCurrently engaged with FDA's Emerging Technologies team regarding the ECO Synthesis platform; no product-specific commercial approvals cited. (2026-08-31)fool.com · sec.gov
Production siteRedwood City, California (headquarters/in-house manufacturing/ECO Innovation Lab); Hayward, California (future GMP manufacturing facility under construction). CMO facilities in Austria, Italy, and the UK. (2026-03-11)ir.codexis.com · codexis.com
Headcount146 full-time and part-time employees. (2025-12-31)ir.codexis.com
Revenue$70.4 million for fiscal year 2025. (2025-12-31)ir.codexis.com

Independent sources: fool.com · sec.gov

Technologies
NameClusterRisk
Biocatalysis in petrochemistryenzymes-biocatalysisLow
Biosynthetic specialty & fine chemicals (precision fermentation, biocatalysis, biorefinery)specialty-fine-chemMedium
Chemoenzymatic API synthesis (biocatalytic small-molecule manufacturing)therapeutics-platformsLow
Enzymatic polymer synthesis in vitroenzymes-biocatalysisMedium
Strain engineering (synbio CRO)crop-biotechMedium

Compiled by BIOECON from primary sources.

Compliance Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.